Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 10, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction involving an increase in the notional allocation of GSK American Depositary Shares (ADSs) within the GSK 401(K) plan:
- Date of Transaction: June 9, 2016
- Price per ADS: $42.06
- Connected Person: Dr. K. Slaoui (Connected Person of Dr. M. M. Slaoui)
- Number of ADSs: 1
- Cause: Revaluation of the cash element of the notional investment.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the identity of Dr. K. Slaoui and their relationship to Dr. M. M. Slaoui.
- Confirm the impact of the 401(K) plan revaluation on the total holdings of the connected person.
- Review the market price of GSK ADSs on June 9, 2016, to validate the reported transaction price of $42.06.